Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Severine Loisel"'
Autor:
Gustavo H. Marin, Samuel Murail, Laura Andrini, Marcela Garcia, Severine Loisel, Pierre Tuffery, Angelita Rebollo
Publikováno v:
Pharmaceutics, Vol 15, Iss 4, p 1180 (2023)
The combination of a tumor-penetrating peptide (TPP) with a peptide able to interfere with a given protein–protein interaction (IP) is a promising strategy with potential clinical application. Little is known about the impact of fusing a TPP with a
Externí odkaz:
https://doaj.org/article/57d6c31cabd7494ca27beb38b98645d3
Autor:
Lorena Simón-Gracia, Severine Loisel, Valeria Sidorenko, Pablo Scodeller, Christophe Parizot, Eric Savier, Tanguy Haute, Tambet Teesalu, Angelita Rebollo
Publikováno v:
Molecular Pharmaceutics
Molecular Pharmaceutics, 2022, 19 (3), pp.895-903. ⟨10.1021/acs.molpharmaceut.1c00837⟩
Molecular Pharmaceutics, 2022, 19 (3), pp.895-903. ⟨10.1021/acs.molpharmaceut.1c00837⟩
International audience; Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. The disease is characterized by the accumulation of tumoral B cells resulting from a defect of apoptosis. We have in vitro and in vivo preclinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92de56d4be36549fa8992869c0c5cd39
https://doi.org/10.1021/acs.molpharmaceut.1c00837
https://doi.org/10.1021/acs.molpharmaceut.1c00837
Autor:
Lorena Simón-Gracia, Eric Savier, Lynda Aoudjehane, Filomena Conti, Tambet Teesalu, Frédéric Charlotte, Jean Yves Brossas, Severine Loisel, Olivier Scatton, Christophe Parizot, Angelita Rebollo
Publikováno v:
Advanced Therapeutics
Advanced Therapeutics, Wiley, 2020, 3 (12), ⟨10.1002/adtp.202000131⟩
Advanced Therapeutics, 2020, 3 (12), ⟨10.1002/adtp.202000131⟩
Advanced Therapeutics, Wiley, 2020, 3 (12), ⟨10.1002/adtp.202000131⟩
Advanced Therapeutics, 2020, 3 (12), ⟨10.1002/adtp.202000131⟩
International audience; Protein-protein interactions are well recognized as therapeutic targets and therefore interfering peptides (IP) that block these interactions are receiving increasing attention. Four different tumor-penetrating peptides (TPPs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3415a4c0254c7d0f402ee31e551bac4c
https://hal-cnrs.archives-ouvertes.fr/hal-03292694
https://hal-cnrs.archives-ouvertes.fr/hal-03292694
Autor:
Jerónimo Bravo, Xiguang Zhang, Lu Tian, Angelita Rebollo, Sylvain Choquet, Etienne Waelkens, Veerle Janssens, Severine Loisel, Jesús Fominaya, Jean Marc Zini, Dorien Haesen
Publikováno v:
International Journal of Peptide Research and Therapeutics. 24:479-488
Protein phosphatase 2A (PP2A) is known to be a negative regulator of several survival and proliferating pathways that are frequently altered in cancer. In addition to chemical enzymatic inhibitors of the PP2A activity, the oncoprotein SET has been de
Autor:
Shaf Keshavjee, S. Hirayama, Jonathan C. Yeung, G. Zehong, Severine Loisel-Meyer, Marcelo Cypel, Jeffrey A. Medin, Masaaki Sato, D. Wagnetz, Mingyao Liu
Publikováno v:
Human Gene Therapy. 22:1453-1460
Obliterative bronchiolitis (OB) is a form of chronic rejection after lung transplantation. Lentiviral vectors (LVs) facilitate long-term gene transduction in many tissues and organs. We hypothesized that lentiviral gene transfer of interleukin (IL)-1
Publikováno v:
Human Gene Therapy
Human Gene Therapy, Mary Ann Liebert, 2010, 21 (5), pp.533--41. ⟨10.1089/hum.2010.033⟩
Human Gene Therapy, Mary Ann Liebert, 2010, 21 (5), pp.533--41. ⟨10.1089/hum.2010.033⟩
Adoptive T cell therapy is aimed at overcoming constraints of the endogenous immune response. In patients with malignancies, this approach is based on the possibility of administering sufficient numbers of tumor-reactive lymphocytes under conditions
Autor:
Robert Kammerer, Nobuo Mizue, Jacopo Mariotti, Wolfgang Zimmermann, Severine Loisel-Meyer, Jason Foley, Miriam E. Mossoba, Boro Dropulic, Daniel H. Fowler, J. Andrea McCart, Tania C. Felizardo, Robert Keefe, Jeffrey A. Medin
Publikováno v:
Molecular Cancer Therapeutics. 8:692-702
The applicability of immunotherapy would be dramatically broadened to a greater number of recipients if direct “off-the-shelf” products could be engineered to engender functionally potent immune responses against true “self”-tumor antigens. T
Autor:
Leon Moussa, Severine Loisel-Meyer, Courtney McDonald, Jeffrey A. Medin, Ashley Colin Emerson-Webber, Natalie Lisa Payne, Guizhi Sun, Claude C.A. Bernard, Christopher Siatskas
Publikováno v:
Brain, behavior, and immunity. 30
Interleukin (IL)-10 is an important immunoregulatory cytokine shown to impact inflammatory processes as manifested in patients with multiple sclerosis (MS) and in its animal model, experimental autoimmune encephalomyelitis (EAE). Several lines of evi
Autor:
Kondala R. Atkuri, Severine Loisel-Meyer, Marco Craveiro, Sandrina Kinet, Marc Sitbon, Louise Swainson, Marion Martinez, Jean-Luc Battini, Cédric Mongellaz, Caroline Costa, Els Verhoeyen, Leal Oburoglu, Naomi Taylor, Leonore A. Herzenberg, François-Loïc Cosset, Leonard A. Herzenberg
Publikováno v:
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences; Vol 109
Proceedings of the National Academy of Sciences; Vol 109
Cell cycle entry is commonly considered to positively regulate HIV-1 infection of CD4 T cells, raising the question as to how quiescent lymphocytes, representing a large portion of the viral reservoir, are infected in vivo. Factors such as the homeos
Publikováno v:
Frontiers in Bioscience. :3202
Immunotherapy against cancer basically aims at either broadly stimulating the immune system or at engineering an immune response against a targeted tumor associated antigen (TAA). In this review, we focus on the translation of immuno-gene therapy str